Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Bupiron

Approved

STANDARD

Bupiron

Rhydburg Pharmaceuticals Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 4ea0b15c75ddfa91
Company: Rhydburg Pharmaceuticals Limited
Type: Standard

Approval Details

Approval Id: 4ea0b15c75ddfa91
Drug Approval Philippines Name: Bupiron
Product Name: Bupiron
Registration Number: DRP-13659
Brand Name: Bupiron
Generic Name: Mupirocin
Dosage Form: Ointment
Dosage Strength: 20 mg/g (2% w/w)
Manufacturer: Rhydburg Pharmaceuticals Limited
Trader: India
Importer: BSD Global Pte. Ltd.
Distributor: Genedrift Philippines OPC
Issuance Date: 29 March 2023
Expiry Date: 29 March 2028
Classification: Over-the-Counter (OTC) Drug

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

4ea0b15c75ddfa91

Type

Standard

Back to Philippines FDA Approvals

Bupiron - Philippines FDA Drug Approval Details